A team of investigators sought to investigate the usefulness of contrast-enhanced harmonic ultrasound-guided fine needle aspiration/biopsy when performed with no on-site cytopathology.
SEQUOIA trial investigators compared pegilodecakin plus FOLFOX with FOLFOX alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Vitamin D is a biomarker of interest in the pancreatic cancer setting.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Investigators compared the outcomes of patients who received pancreatic enzyme replacement therapy (PERT) with those who did not.
The ARC-8 study evaluated whether AB680, the anti-PD-1 antibody zimberelimab, and chemotherapy could improve metastatic pancreatic adenocarcinoma (PDAC) outcomes.
Preliminary data suggest that neoadjuvant treatment of resected pancreatic cancer with urelumab plus nivolumab and GVAX was well tolerated and showed some antitumor activity in a small study.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
